All amounts are in U.S. dollars
QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the second quarter ended June 30, 2008.
Second Quarter 2008 Highlights
- Advancement of cetrorelix Phase 3 program in BPH;
- First efficacy trial: patient enrollment completed;
- Second efficacy trial: patient enrollment ongoing / completion
planned for third quarter of 2008 remains on target;
- Safety trial: first patient dosing initiated.
- Completion of sale of Quebec City building for $7.1 million.
Juergen Ernst, Chairman, Interim President and CEO at AEterna Zentaris commented, "During the quarter, we achieved our key objectives as our Phase 3 program in BPH with our lead compound cetrorelix met all recruitment goals and remains on track, with first results expected in the third quarter of 2009. Furthermore, we monetized our Quebec City building which provided additional non-dilutive funding. Over the next few months, we will focus on advancing our Phase 3 program in BPH with cetrorelix, while we endeavour to conclude additional non-dilutive transactions and strategic partnerships."
CONSOLIDATED RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2008
Consolidated sales and royalties increased to $8.2 million for the
three-month period ended June 30, 2008, compared to $7.7 million for the
same period in 2007. The increase in sales and royalties for the
three-month period ended June 30, 2008 is related primarily to additional
sales of Cetrotide(R), partly offset by the exclusion of sales from
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2008 PR Newswire.
All rights reserved